Clay Siegall; A Proven Leader in The Biopharmaceutical Industry

The founder and current CEO of Seattle Genetic, Dr. Clay Siegall is a trained scientist specializing in targeted cancer therapies. His company specializes in research and development of Drugs to the treat types of cancer that have received little attention over the years. A holder of B.S in Zoology and Ph.D. in Genetics, he says he always had an interest in medicine and a desire to use the power of technology to overcome diseases. Though he admits that there are huge risks in running a biopharmaceutical industry, he accounts his love for work and different working habits as the pillars that have seen him through.

 

Before co-founding Seattle Genetics in 1998, Dr. Siegall first worked at the National Cancer Institute, National Institutes of Health between 1988 and 1991 and later as a leading researcher at Bristol-Myers Squibb Pharmaceutical Research Institute until 1997. As the president of Seattle Genetic, Dr. Siegall has guided the company to be the world’s leader in the development of ADCs, antibody-Drug conjugates. In 2011 the FDA approved the company’s first ADC product, ADCETRIS®. Today, ADCETRIS is approved in at least 65 countries making it a global brand. Besides, there has been a continued advancement by Seattle Genetics in the diverse pipeline of proprietary ADCs for cancer treatment.

 

Seattle Genetic has under DR. Siegall’s leadership entered into numerous strategic ADC technology licenses. These technologies have to date generated an estimated income of $350 million. Through private and public funding, DR. Siegall has also guided Seattle Genetics to securing over $1.2 billion. His outstanding performance as a leader at Seattle Genetic has seen Dr. Siegall appointed as a director in various biopharmaceutical and biotechnology companies.

 

In 2014, he earned an appointment to the board of trustees at Ultragenyx Pharmaceutical where he gained recognition as a proven leader in the biopharmaceutical industry. At the time of the designation, Dr. Siegall was already a Director of Mirna Therapeutics and Alder Biopharmaceuticals. As an entrepreneur and a leader, Dr. Clay Siegall recommends entrepreneurs to be lifelong learners and collaborate with other successful industry leaders who will help in the manifestation of ideas and approaches.

 

Eric Lefkofsky the Tempus CEO who is Committed in the Fight against cancer

Cancer is one of the dreaded diseases that are claiming so many lives. A lot of people across the world are taking a step to escalate the fight against the disease either by funding research or contributing their resources to help in the building of modern treatment facilities. Mr Eric Lefkofsky, the CEO of Tempus, has founded a startup that has a particular focus on fighting breast cancer. Tempus is developing ways to provide doctors from the University of Chicago with data that will improve the management of breast cancer.

Tempus is a firm based in Chicago, and it has signed an agreement with the department of medicine at the University of Chicago to offer molecular analysis and sequencing services to cancer experts at the UChicago breast cancer center. This will improve the specialists approach on cancer, and it will benefit patients. Eric’s firm is looking forward towards analyzing over 1000 breast cancer cases; this will assist researchers and medical practitioners to make predictions on how different patients respond to different cancer therapies.

The primary goal is to make breast cancer treatment more efficient and help patients to get more positive results. Breast cancer is a common type of cancer, but over the years doctors have not been able to retrieve information on the many patients who have received therapy. Lack of necessary genetic information about the patient has made doctors unable to accord patients the right treatment. This partnership between Tempus and the University of Chicago department of medicine will improve cancer treatment. The university will build the best molecular data set to help in the fight against cancer.

Tempus has the latest equipment that assists them in genomic sequencing, which supports doctors to make timely decisions on the most efficient treatment for breast cancer. Tempus Head offices are in 600.W Chicago.

Eric Lefkofsky is an entrepreneur in the technology sector. He is also among the founders of Lightbank, a company that is very active in disruptive technologies. Eric is the Groupon chairperson, a firm that is a recognized e-commerce platform.Eric runs the Lefkofsky Family Foundation, a very ongoing charity initiative. Eric graduated from the University of Michigan and got his Juris Doctor at the University of Michigan law school.

http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life

Eric Lefkofsky Asserts that Business May Spell the End of Cancer

 

Billionaires typically think bigger than the rest of us; maybe that’s why they’re billionaires. Rarely are their thoughts more apparent than in The Giving Pledge, formed in 2010 to fuel philanthropy among the world’s wealthy elite. Some 154 billionaires in 16 countries had joined the organization as of June of 2016, with co-founder Bill Gates expressing surprise at the outpouring of support and another member fueling a dream infinitely larger than dollars and cents.

His name is Eric Lefkofsky, whom you may know as the founder of Groupon, an e-commerce site linking local consumers and merchants through offers on goods and services. His longer-term goals rest with Chicago’s Tempus Health Inc., of which he is chief executive officer.

Tempus’ ideal is to assist physicians in the care of cancer patients by providing real-time technology-driven data on the disease — data resulting from the years-long technological explosion that reveals them. Mathematicians, computational biologists, data analysts and software engineers team with doctors and clinicians in a search for the best possible medical results.

“We now can gather incredibly rich… data,” Leofsky says in a film on the firm, “but how do we analyze it? How do we help physicians while they’re treating a patient that might actually improve outcomes? That’s what Tempus is delivering.”

Tempus is currently focused on the treatment of breast, lung and pancreatic cancers.

Lefkofsky calls his approach to Tempus one of “accelerated disruption,” with technology leading the way in determining the pace of world commerce. Gone, he would say, are the days of the rotely sealed contract inside a smoke-filled board room.

“Disruptive companies,” Lefkofsky writes on the website accelerateddisruption.com, “are born every day. Someone has a great idea that offers a better choice in terms of price, convenience, service or functionality, and for a moment, they hold the keys to the remaking of an entire industry. Businesses that can understand and control the forces of technology will thrive in the coming years.”

The Giving Pledge is arguably delighted with its contributions from The Lefkofsky Family Foundation, which funds several Chicago-area programs in education, medicine, the arts and human rights endeavors. With Tempus, Lefkofsky has a state-of-the-art company designed to enhance and prolong the lives of those programs’ beneficiaries.

Lefkofsky, 47, is a Detroit native and a 1993 University of Michigan law school graduate.

Seigall Steers Seattle Genetics in Revolutionizing Cancer Treatments and Therapies

Entrepreneur and scientist Clay B. Seigall is one of the driving forces behind a number of pharmaceutical companies in the U.S. In 1998, he co-founded Seattle Genetics – a scientific foundation aimed at innovating ways on helping patients. During the course of his stay, Seigall steered the company towards establishing the antibody-drug conjugates designed for the treatment of cancer. It was also Siegall who scored a $300 million worth of multiple Antibody Drug Conjugates (ADC) licenses with Genentech (Roche), GlaxoSmithKline, AbbVie, and Pfizer. Siegall led Seattle Genetics into generating more than $675 million including its IPO in 2001.

In a keynote speech during the 5th Annual ADC, Seigall noted a successful FDA approval of the Biologics License Application for ADCETRIS to be used for post-transplant treatment of Hodgkin lymphoma (HL) patients. This is a breakthrough considering that 50 percent of HL patients who underwent autologous stem cell transplant are likely to have relapse. Seattle Genetics is also working on three-phase trials on ALCANZA, ECHELON-1, and ECHELON-2 which are potential label expansion for ADCETRIS.

ADC development holds a brighter yet challenging future in becoming a highly-specific tumor antigen. For the past 17 years, Seattle Genetics has made significant investments to products specific to cancer treatment. Currently, the company is working on SGN-CD33A and SGN-CD19A. SGN-CD33A is intended as a new treatment for acute myeloid leukemia. On the other hand, SGN-CD33A allows the cell-killing PBD dimer to release cytotoxic chemicals into CD33-positive cells.

Currently, Siegall serves as the chair of the Board of Directors at Ultragenyx Pharmaceuticals and Mirna Therapeutics, Inc. He also holds the same position in Alder Biopharmaceuticals, Inc. since 2006. After finishing his Zoology degree at the University of Maryland, Siegall pursued a Doctor of Philosophy major in Genetics at The George Washington University.

Like Seattle Genetics, Mirna is focused on cancer research, with a specialization in microRNA therapeutics. miRNAs are hardwired in the human genome and are used as natural regulators of the overall gene expression. There are approximately 1,400 miRNAs in the human genome, comprising at least 2 percent of the mammalian genes. Founded in 2007, Mirna Therapeutics has received funding from private and public entities including the State of Texas and the Cancer Prevention and Research Institute of Texas.

Learn more:

http://seekingalpha.com/article/3969434-seattle-genetics-sgen-clay-b-siegall-q1-2016-results-earnings-call-transcript

http://executives.findthecompany.com/l/23957/Dr-Clay-B-Siegall-PhD